General practice

Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers

^a Department of Social and Preventive Medicine, Monash University, Melbourne, Australia 3168, ^b Ciba-Geigy New Zealand, Auckland, New Zealand

Correspondence to: Dr Gourlay.

Abstract

Objective: To assess the efficacy and safety of a repeat course of treatment with transdermal nicotine for cessation of smoking in a brief intervention setting.
Study design: Randomised, double blind, placebo controlled trial with follow up for 26 weeks.
Subjects: 629 smokers who had unsuccessfully attempted to stop smoking by using active transdermal nicotine and brief behavioural counselling. Smokers were motivated to quit smoking for a second time and smoked >/=15 cigarettes a day.
Interventions: Twelve weeks' treatment with active transdermal nicotine patches or placebo and brief counselling at monthly visits.
Main outcome measure: Sustained smoking cessation for the 28 days before the visit at week 12 verified by expired carbon monoxide concentrations.
Results: At 12 weeks 21/315 (6.7%) subjects allocated to active treatment had stopped smoking compared with 6/314 (1.9%) allocated to placebo (absolute difference 4.7%; 95% confidence interval 1.6% to 7.9%; P=0.003). At 26 weeks the rates were 20/315 (6.4%) and 8/314 (2.6%) (3.8%; 0.6% to 7.0%; P=0.021). Difficulty in sleeping was reported by 43/179 (24.0%) on active treatment and 19/143 (13.3%) on placebo (P=0.015). Severe reactions at the site of application were rare (6/322; 1.9%).
Conclusions: Repeated treatment with transdermal nicotine together with brief counselling can improve the low success rates of smoking cessation in recently relapsed, moderate to heavy smokers. Questions remain about whether more intensive interventions or higher doses of nicotine could be more effective. The likelihood of severe reactions at the site of application with repeated treatment is low.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

This article has been cited by other articles:

• Cupertino, A. P., Wick, J. A., Richter, K. P., Mussulman, L., Nazir, N., Ellerbeck, E. F. (2009). The Impact of Repeated Cycles of Pharmacotherapy on Smoking Cessation: A Longitudinal Cohort Study. Arch Intern Med 169: 1928-1930 [Full text]  
• Nosyk, B., MacNab, Y. C., Sun, H., Fischer, B., Marsh, D. C., Schechter, M. T., Anis, A. H. (2009). Proportional Hazards Frailty Models for Recurrent Methadone Maintenance Treatment. Am J Epidemiol 170: 783-792 [Abstract] [Full text]  
• Ellerbeck, E. F., Mahnken, J. D., Cupertino, A. P., Cox, L. S., Greiner, K. A., Mussulman, L. M., Nazir, N., Shireman, T. I., Resnicow, K., Ahluwalia, J. S. (2009). Effect of Varying Levels of Disease Management on Smoking Cessation: A Randomized Trial. ANN INTERN MED 150: 437-446 [Abstract] [Full text]  
• Eisenberg, M. J. MD MPH, Filion, K. B. MSc, Yavin, D. BSc, Belisle, P. MSc, Mottillo, S. BSc, Joseph, L. PhD, Gervais, A. MD, O'Loughlin, J. PhD, Paradis, G. MD MSc, Rinfret, S. MD MSc, Pilote, L. MD PhD (2008). Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179: 135-144 [Abstract] [Full text]  
• Prochazka, A. V. (2000). New Developments in Smoking Cessation. Chest 117 : 169S-175S [Abstract] [Full text]  
• Hughes, J. R., Goldstein, M. G., Hurt, R. D., Shiffman, S. (1999). Recent Advances in the Pharmacotherapy of Smoking. JAMA 281: 72-76 [Abstract] [Full text]